Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084382 | 0.85 | HPGD (0.38) | HPGDLMNAMEN1KMT2A | |
| SCHEMBL22084413 | 0.84 | HPGD (0.38) | HPGDLMNAMEN1KMT2A | |
| SCHEMBL22084414 | 0.83 | LPL (0.43) | HPGDLMNA | |
| SCHEMBL22084380 | 0.82 | HPGD (0.41) | HPGDMEN1KMT2A | |
| SCHEMBL22084689 | 0.82 | HPGD (0.36) | HPGDLMNA | |
| SCHEMBL22084391 | 0.81 | HPGD (0.39) | HPGDLMNAMAPTMEN1KMT2A | |
| SCHEMBL22084420 | 0.81 | HPGD (0.39) | HPGDLMNAMAPTMEN1KMT2A | |
| SCHEMBL22084696 | 0.81 | HPGD (0.45) | HPGDMEN1KMT2A | |
| SCHEMBL22084393 | 0.80 | HPGD (0.40) | HPGDLMNAMEN1KMT2A | |
| SCHEMBL14826582 | 0.77 | HPGD (0.59) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020117938-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-06-11 | — | — | WO | disclosed |